Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.35B
• Dividend Yield: N/A
• Average Volume (3M): 9.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: -2.37%
• EPS Growth: 77.85%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.28
• Shares Outstanding: 177,473,400
• 10 Day Avg. Volume: 10,543,906
• 30 Day Avg. Volume: 9,795,440
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.60
• P/FCF Ratio: 5.48
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 0.95
• Enterprise Value/Ebitda: -36.23
• 1Y Price Target: $9.69
• Price Target Upside: 28.69% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12
• EPS Forecast (FY): -1.15
• Revenue Forecast (FY): $2.52B

• Rating: 48 Neutral
• Price Target: $7.50 ▼(-0.40% Downside)

Teladoc's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges with declining revenue growth and persistent losses. Technical indicators suggest bearish momentum. While the earnings call provided some positive insights, challenges in key segments and valuation concerns weigh heavily on the stock's outlook.

Positive Factors

Product Innovation

Teladoc's focus on product innovation, such as launching Wellbound and enhancing health programs, strengthens its competitive position and service offerings, potentially leading to increased customer engagement and market share.

International Expansion

International expansion is a key growth driver for Teladoc, with significant revenue contribution, enhancing its global footprint and diversifying its revenue streams, which is crucial for long-term growth.

Integrated Care Segment Growth

Growth in the Integrated Care segment indicates strong demand and effective service delivery, supporting Teladoc's strategy to expand comprehensive healthcare solutions and improve market penetration.

Negative Factors

Declining Revenue Growth

Declining revenue growth reflects challenges in maintaining market momentum and could impact Teladoc's ability to scale efficiently, posing risks to future profitability and market competitiveness.

BetterHelp Revenue Decline

The decline in BetterHelp revenue and user base highlights challenges in the mental health segment, potentially affecting Teladoc's growth prospects and necessitating strategic adjustments.

Increased Customer Acquisition Costs

Rising customer acquisition costs and higher churn rates indicate inefficiencies in user retention strategies, which could pressure margins and hinder sustainable growth.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. (TDOC) is a leading telehealth company that provides a wide range of virtual healthcare services. The company operates primarily in the healthcare sector, offering services such as virtual medical consultations, mental health support, chronic condition management, and wellness programs. Teladoc's platform connects patients with healthcare professionals through phone, video, and mobile applications, making healthcare more accessible and convenient for individuals across various demographics and geographies.

How the Company Makes Money

Teladoc generates revenue through a subscription-based model and per-visit fees. Its primary revenue streams include membership fees from health plans, employers, and health systems, which provide access to its telehealth services for their members. Additionally, Teladoc earns revenue from pay-per-visit consultations where patients pay for individual visits to healthcare providers. The company has established significant partnerships with insurance companies and employers, enhancing its reach and utilization. Moreover, Teladoc has expanded its offerings through acquisitions and collaborations, further diversifying its revenue streams and enhancing its service capabilities.

Teladoc Financial Statement Overview

Summary

Teladoc faces significant financial challenges, with declining revenue growth and persistent losses impacting profitability. Despite a stable gross profit margin and improved cash flow, negative net margins and return on equity highlight ongoing operational inefficiencies. The balance sheet shows moderate leverage, but profitability remains a concern.

Income Statement

Teladoc's income statement reveals a challenging financial landscape. The company has experienced declining revenue growth, with a significant drop in the TTM period. Gross profit margins remain healthy at over 70%, but the net profit margin is negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite these challenges, the company has managed to maintain a stable gross profit margin over time.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, which has improved in the TTM period, indicating better leverage management. However, the return on equity is negative, highlighting profitability issues. The equity ratio remains stable, suggesting a balanced asset structure, but the overall financial health is weakened by persistent losses.

Cash Flow

Teladoc's cash flow statement shows some positive trends, with a notable increase in free cash flow growth in the TTM period. The operating cash flow to net income ratio has improved, indicating better cash generation relative to net losses. However, the free cash flow to net income ratio suggests that cash flow improvements are not yet sufficient to cover net losses fully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.53B	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.76B	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-46.47M	31.72M	43.61M	-7.54M	-31.42M	-354.49M
Net Income	-223.59M	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	2.88B	3.52B	4.39B	4.35B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	726.25M	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.03B	1.58B	1.59B	1.57B	1.27B	1.47B
Total Liabilities	1.49B	2.03B	2.07B	2.04B	1.69B	1.87B
Stockholders Equity	1.39B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	256.60M	282.89M	193.67M	16.53M	130.06M	-79.55M
Operating Cash Flow	292.52M	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-261.33M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	-550.70M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Negative. The current price of 7.53 is below the 20-day moving average (MA) of 8.50, below the 50-day MA of 8.24, and below the 200-day MA of 8.30, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 40.67 is Neutral, neither overbought nor oversold. The STOCH value of 8.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	67 Neutral	$762.08M	37.91	5.87%	0.48%	3.68%	5.62%
SOPH	57 Neutral	$316.27M	-4.26	-86.09%	―	13.66%	-2.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	49 Neutral	$746.18M	―	-13.63%	―	-16.65%	-71.92%
TDOC	48 Neutral	$1.35B	―	-15.42%	―	-2.37%	77.85%
HCAT	48 Neutral	$214.64M	―	-28.42%	―	5.55%	-0.99%
AMWL	45 Neutral	$81.57M	―	-38.35%	―	4.33%	50.50%

Teladoc Corporate Events

Teladoc Health’s Earnings Call: Resilience Amid Challenges

Teladoc Health’s recent earnings call painted a picture of resilience and growth, tempered by a few challenges. The company exceeded its revenue and EBITDA guidance midpoints, showcasing strong international growth and expansion in the mental health sector. However, hurdles in BetterHelp’s U.S. cash pay segment and a goodwill impairment charge have added some clouds to the otherwise promising outlook.

Teladoc Health Reports Q3 2025 Financial Results

Teladoc Health, Inc. is a leading global provider of virtual healthcare services, offering a comprehensive range of medical and wellness solutions through its Integrated Care and BetterHelp segments. The company is recognized for its innovative approach to healthcare delivery, enhancing access and outcomes while reducing costs.

Teladoc’s New Study Explores Digital Solutions for Mental Health

Teladoc Inc. has announced a new clinical study titled ‘A Feasibility Randomized Controlled Trial Evaluating the Effectiveness of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety.’ The study aims to assess the clinical outcomes of a digital mental health intervention, focusing on its feasibility and effectiveness in treating moderate to severe depression and anxiety. This trial is significant as it explores innovative digital solutions for mental health issues, potentially offering scalable and accessible care options.

Teladoc CFO Mala Murthy to Resign in November

Teladoc Health announced that its Chief Financial Officer, Mala Murthy, will resign effective November 21, 2025, to pursue an opportunity outside the healthcare industry. The company has begun searching for a new CFO and will implement an interim leadership structure to ensure a smooth transition. In addition, Teladoc reaffirmed its full-year 2025 financial outlook and provided preliminary third-quarter financial results, reporting $626.4 million in revenue and $69.9 million in adjusted EBITDA.

The most recent analyst rating on (TDOC) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.